• Je něco špatně v tomto záznamu ?

Cell-free DNA - Minimally invasive marker of hematological malignancies

V. Kubaczkova, D. Vrabel, L. Sedlarikova, L. Besse, S. Sevcikova,

. 2017 ; 99 (4) : 291-299. [pub] 20170803

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc18024859

Grantová podpora
NV15-29508A MZ0 CEP - Centrální evidence projektů

Although tumor cells are the most reliable source of tumor DNA, biopsy of the tumor is an invasive procedure that should be avoided in some cases. The main limitation of any biopsy is sampling of one tumor site, which may not represent all malignant clones due to the heterogeneity of the tumor. These clones respond to treatment differently and thus directly influence survival of the patient. Circulating cell-free DNA (cfDNA) is released from multiple tumor sites, reflects overall heterogeneity of the tumor, and correlates with its progression. Detection of tumor-specific genetic and epigenetic aberrations in cfDNA could have a direct impact on molecular diagnosis, prognosis, follow-up of disease, monitoring of minimal residual disease, and response to treatment. While most cfDNA data are still experimental, they are very promising. This review focuses on cfDNA in hematological malignancies.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024859
003      
CZ-PrNML
005      
20201031161219.0
007      
ta
008      
180709s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/ejh.12925 $2 doi
035    __
$a (PubMed)28692178
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kubaczkova, Veronika $u Faculty of Medicine, Babak Myeloma Group, Department of Pathological Physiology, Masaryk University, Brno, Czech Republic.
245    10
$a Cell-free DNA - Minimally invasive marker of hematological malignancies / $c V. Kubaczkova, D. Vrabel, L. Sedlarikova, L. Besse, S. Sevcikova,
520    9_
$a Although tumor cells are the most reliable source of tumor DNA, biopsy of the tumor is an invasive procedure that should be avoided in some cases. The main limitation of any biopsy is sampling of one tumor site, which may not represent all malignant clones due to the heterogeneity of the tumor. These clones respond to treatment differently and thus directly influence survival of the patient. Circulating cell-free DNA (cfDNA) is released from multiple tumor sites, reflects overall heterogeneity of the tumor, and correlates with its progression. Detection of tumor-specific genetic and epigenetic aberrations in cfDNA could have a direct impact on molecular diagnosis, prognosis, follow-up of disease, monitoring of minimal residual disease, and response to treatment. While most cfDNA data are still experimental, they are very promising. This review focuses on cfDNA in hematological malignancies.
650    12
$a nádorové biomarkery $7 D014408
650    12
$a cirkulující nádorová DNA $7 D000074141
650    _2
$a genetická variace $7 D014644
650    _2
$a hematologické nádory $x krev $x diagnóza $x genetika $7 D019337
650    _2
$a lidé $7 D006801
650    _2
$a tekutá biopsie $7 D000073890
650    _2
$a diagnostické techniky molekulární $7 D025202
650    _2
$a prognóza $7 D011379
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Vrabel, David $u Department of Chemistry and Toxicology, Veterinary Research Institute, Brno, Czech Republic.
700    1_
$a Sedlarikova, Lenka $u Faculty of Medicine, Babak Myeloma Group, Department of Pathological Physiology, Masaryk University, Brno, Czech Republic.
700    1_
$a Besse, Lenka $u Experimental Oncology and Hematology, Department of Oncology and Hematology, Cantonal Hospital St Gallen, St Gallen, Switzerland.
700    1_
$a Sevcikova, Sabina $u Faculty of Medicine, Babak Myeloma Group, Department of Pathological Physiology, Masaryk University, Brno, Czech Republic.
773    0_
$w MED00001620 $t European journal of haematology $x 1600-0609 $g Roč. 99, č. 4 (2017), s. 291-299
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28692178 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20201031161219 $b ABA008
999    __
$a ok $b bmc $g 1316990 $s 1021780
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 99 $c 4 $d 291-299 $e 20170803 $i 1600-0609 $m European journal of haematology $n Eur J Haematol $x MED00001620
GRA    __
$a NV15-29508A $p MZ0
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Možnosti archivace